Germany · Delayed Price · Currency is EUR Galectin Therapeutics Company Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases.
Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.
Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration.
The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011.
Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
| Country | United States |
| Founded | 2000 |
| Industry | Pharmaceutical Preparations |
| Employees | 15 |
| CEO | Joel Lewis |
Contact Details
Address: 4960 Peachtree Industrial Boulevard Norcross, Nevada 30071 United States | |
| Phone | 678 620 3186 |
| Website | galectintherapeutics.com |
Stock Details
| Ticker Symbol | PHPN |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joel Lewis | Chief Executive Officer |
| Jack Callicutt | Chief Financial Officer |